Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations
JCO Oncology Practice · 2025-03 · 21 (3) · 267-269
DOI: 10.1200/op-24-00501 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Oncology Practice, 2025-03. Verfasst von Arjun Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Divsion of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Time and other considerations when evaluating a switch to newer drug formulations (eg, subQ vs IV).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Divsion of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN.
- National Breast Cancer Coalition, Washington, DC.
- Pharmacy Services, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT.
- Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
ORCID-Profile: Arjun Gupta, Makala B Pace, Rachel I Vogel
Förderung
- NCI NIH HHS
Zitieren
APA
Gupta, A., Tregear, M., Pace, M. B., & Vogel, R. I. (2025). Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations. JCO Oncology Practice, 21(3), 267-269. https://doi.org/10.1200/op-24-00501
Vancouver
Gupta A, Tregear M, Pace MB, Vogel RI. Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations. JCO Oncology Practice. 2025;21(3):267-269. doi:10.1200/op-24-00501
BibTeX
@article{Gupta2025,
author = {Gupta, Arjun and Tregear, Michelle and Pace, Makala B and Vogel, Rachel I},
title = {Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {3},
pages = {267--269},
doi = {10.1200/op-24-00501}
}
EUVIMED